RxDoctor Payments DataLook up a doctor →

Kristen Hebert, PA

Physician Assistant · Zachary, LANPI 1093268963

Payments from drug & device makers

$27,380in general payments, 2019–2025

Across 958 payments — averaging $28.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$8K
  • AbbVie$4K
  • LEO Pharma Inc.$2K
  • Lilly USA, LLC$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • UCB, Inc.$1K
  • plus $10K from 28 others

What the payments were for

  • Consulting fees$2,0387%
  • Speaking & faculty fees$7,05026%
  • Food & beverage$17,75765%
  • Education$5352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,380 in reported general payments places this provider in the 95th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$4,839
Medicare patients
27
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SotyktuDeucravacitinib18$118,617
OtezlaApremilast12$57,219
Clobetasol Propionate132$4,806
Fluorouracil22$1,193
Triamcinolone Acetonide113$1,080
Ketoconazole58$1,046
Doxycycline Monohydrate46$871
Doxycycline Hyclate39$714
Metronidazole11$578
ValacyclovirValacyclovir Hcl21$562
Hydrocortisone11$478
Dutasteride11$257
Minoxidil26$171
Gabapentin18$146
Mupirocin16$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sotyktu$665$118,61718 claims
AmgenOtezla$826$57,21912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Zachary

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →